Galectin Therapeutics(GALT)
(GALT)
Kvartalsrapport (Q4)
35 dager siden
Ordredybde
Stengt
Antall
Kjøp
0
Selg
Antall
0
Siste handler
| Tid | Pris | Antall | Kjøpere | Selger |
|---|---|---|---|---|
| - | - | - | - |
Volumvektet snittpris (VWAP)
-Volumvektet snittpris (VWAP)
-Omsetning (USD)
842 139Meglerstatistikk
Fant ingen data
Selskapshendelser
| Kommende | |
|---|---|
Selskapskalender ikke tilgjengelig | |
| Historisk | ||
|---|---|---|
| 2023 Kvartalsrapport (Q4) | 29. mars | |
| 2023 Årsrapport | 29. mars | |
| 2023 Generalforsamling | 7. des. 2023 | |
| 2023 Kvartalsrapport (Q3) | 13. nov. 2023 | |
| 2023 Kvartalsrapport (Q2) | 14. aug. 2023 |
Data hentes fra Morningstar
Nyheter og Analyser
Nyheter og/eller generelle investeringsanbefalinger, eller utdrag av disse på denne siden og øvrige lenker, er produsert og levert av den spesifiserte leverandøren. Nordnet har ikke deltatt i utarbeidelsen, og har ikke gjennomgått eller gjort endringer i materialet. Les mer om investeringsanbefalinger.
Kvartalsrapport (Q4)
35 dager siden
Nyheter og Analyser
Nyheter og/eller generelle investeringsanbefalinger, eller utdrag av disse på denne siden og øvrige lenker, er produsert og levert av den spesifiserte leverandøren. Nordnet har ikke deltatt i utarbeidelsen, og har ikke gjennomgått eller gjort endringer i materialet. Les mer om investeringsanbefalinger.
Selskapshendelser
| Kommende | |
|---|---|
Selskapskalender ikke tilgjengelig | |
| Historisk | ||
|---|---|---|
| 2023 Kvartalsrapport (Q4) | 29. mars | |
| 2023 Årsrapport | 29. mars | |
| 2023 Generalforsamling | 7. des. 2023 | |
| 2023 Kvartalsrapport (Q3) | 13. nov. 2023 | |
| 2023 Kvartalsrapport (Q2) | 14. aug. 2023 |
Data hentes fra Morningstar
Shareville
Bli med i samtalen på SharevilleEt fellesskap av investorer som deler innsikt og kunnskap i sine porteføljer.
Logg inn
27. feb.27. feb.Samme produkt som det der lige har sendt Zealand i himlen- 2. aug. 20222. aug. 2022Så kører vi igen - håber den ryger helt til tops denne gang
- 7. jan. 20227. jan. 2022Den har godt nok taget nogle op og nedture kan ikke finde en specifik begrundelse for det seneste nose dive - heldigvis kun under lille omsaetning
15. jan. 201915. jan. 2019Det här kan vara första signalen att ett uppköp äntligen är på gång. Fingers crossed. "Galectin Therapeutics’ Largest Institutional Shareholder Converts Existing Series B Preferred Stock Into Common Stock Streamlining Its Capital Structure" https://finance.yahoo.com/news/galectin-therapeutics-largest-institutional-shareholder-130000609.html15. jan. 201915. jan. 2019"Harold H. Shlevin, Ph.D., President and Chief Executive Officer of Galectin Therapeutics, said, “10X Fund has been a significant investor and supporter of Galectin Therapeutics for many years. We are pleased with their recent decision to convert all their existing Series B Preferred Stock ownership into common shares of the Company. This conversion improves our financial flexibility by expanding our access to the capital markets by not only simplifying our capital structure but also eliminating private equity like rights and protective provisions to which many institutional investors had objected."- 21. juni 201821. juni 2018“ It’s clear from this data that the target population should be patient’s w/o varices. Furthermore, in the GR2 and GR8 groups 0/25 and 1/23 patients formed new varices respectfully compared to 6/33 in the placebo. The phase 3 endpoint could be whether or not patients developed varices, but that is up to GALT and the FDA to negotiate. On the surface it is clear that the drug halts NASH progression preventing the formation of new varices, and yes, this was statistically significant in GR2 group. Moreover, the investigation into liver inflammation/histology had a statistically significant (P=.01) reduction in hepatocyte ballooning in the GR2 group. Lastly, there were no safety concerns and the GR was well tolerated. The take away? GALT has developed a drug effective at treating late stage NASH cirrhosis, especially in patient’s w/o varices and with mild portal hypertension (an unmet medical need). Given the statistical significance in the sub-group the Phase 3 (P3) should confirm this. At the last FDA meeting with GALT they agreed for the target population in P3 to be patient’s w/o varices and the primary endpoints to be either change in HVPG or the progression of varices (both of which were achieved in p2 in patient’s w/o varices). GALT is positioned to blow P3 out of the water and gain FDA approval. Not to mention there will be an interim analysis which can get the drug approved even quicker.” http://psinvestor.com/galectin-therapeutics-from-an-investor-perspective/
Kommentarene ovenfor kommer fra brukere på Nordnets sosiale nettverk Shareville og er verken redigert eller forhåndsvist av Nordnet. De innebærer ikke at Nordnet gir investeringsråd eller investeringsanbefalinger. Nordnet påtar seg ikke ansvar for kommentarene.
Kvartalsrapport (Q4)
35 dager siden
Nyheter og Analyser
Nyheter og/eller generelle investeringsanbefalinger, eller utdrag av disse på denne siden og øvrige lenker, er produsert og levert av den spesifiserte leverandøren. Nordnet har ikke deltatt i utarbeidelsen, og har ikke gjennomgått eller gjort endringer i materialet. Les mer om investeringsanbefalinger.
Shareville
Bli med i samtalen på SharevilleEt fellesskap av investorer som deler innsikt og kunnskap i sine porteføljer.
Logg inn
- 27. feb.27. feb.Samme produkt som det der lige har sendt Zealand i himlen
- 2. aug. 20222. aug. 2022Så kører vi igen - håber den ryger helt til tops denne gang
- 7. jan. 20227. jan. 2022Den har godt nok taget nogle op og nedture kan ikke finde en specifik begrundelse for det seneste nose dive - heldigvis kun under lille omsaetning
- 15. jan. 201915. jan. 2019Det här kan vara första signalen att ett uppköp äntligen är på gång. Fingers crossed. "Galectin Therapeutics’ Largest Institutional Shareholder Converts Existing Series B Preferred Stock Into Common Stock Streamlining Its Capital Structure" https://finance.yahoo.com/news/galectin-therapeutics-largest-institutional-shareholder-130000609.html15. jan. 201915. jan. 2019"Harold H. Shlevin, Ph.D., President and Chief Executive Officer of Galectin Therapeutics, said, “10X Fund has been a significant investor and supporter of Galectin Therapeutics for many years. We are pleased with their recent decision to convert all their existing Series B Preferred Stock ownership into common shares of the Company. This conversion improves our financial flexibility by expanding our access to the capital markets by not only simplifying our capital structure but also eliminating private equity like rights and protective provisions to which many institutional investors had objected."
- 21. juni 201821. juni 2018“ It’s clear from this data that the target population should be patient’s w/o varices. Furthermore, in the GR2 and GR8 groups 0/25 and 1/23 patients formed new varices respectfully compared to 6/33 in the placebo. The phase 3 endpoint could be whether or not patients developed varices, but that is up to GALT and the FDA to negotiate. On the surface it is clear that the drug halts NASH progression preventing the formation of new varices, and yes, this was statistically significant in GR2 group. Moreover, the investigation into liver inflammation/histology had a statistically significant (P=.01) reduction in hepatocyte ballooning in the GR2 group. Lastly, there were no safety concerns and the GR was well tolerated. The take away? GALT has developed a drug effective at treating late stage NASH cirrhosis, especially in patient’s w/o varices and with mild portal hypertension (an unmet medical need). Given the statistical significance in the sub-group the Phase 3 (P3) should confirm this. At the last FDA meeting with GALT they agreed for the target population in P3 to be patient’s w/o varices and the primary endpoints to be either change in HVPG or the progression of varices (both of which were achieved in p2 in patient’s w/o varices). GALT is positioned to blow P3 out of the water and gain FDA approval. Not to mention there will be an interim analysis which can get the drug approved even quicker.” http://psinvestor.com/galectin-therapeutics-from-an-investor-perspective/
Kommentarene ovenfor kommer fra brukere på Nordnets sosiale nettverk Shareville og er verken redigert eller forhåndsvist av Nordnet. De innebærer ikke at Nordnet gir investeringsråd eller investeringsanbefalinger. Nordnet påtar seg ikke ansvar for kommentarene.
Ordredybde
Stengt
Antall
Kjøp
0
Selg
Antall
0
Siste handler
| Tid | Pris | Antall | Kjøpere | Selger |
|---|---|---|---|---|
| - | - | - | - |
Volumvektet snittpris (VWAP)
-Volumvektet snittpris (VWAP)
-Omsetning (USD)
842 139Meglerstatistikk
Fant ingen data
Selskapshendelser
| Kommende | |
|---|---|
Selskapskalender ikke tilgjengelig | |
| Historisk | ||
|---|---|---|
| 2023 Kvartalsrapport (Q4) | 29. mars | |
| 2023 Årsrapport | 29. mars | |
| 2023 Generalforsamling | 7. des. 2023 | |
| 2023 Kvartalsrapport (Q3) | 13. nov. 2023 | |
| 2023 Kvartalsrapport (Q2) | 14. aug. 2023 |
Data hentes fra Morningstar